Filing Flows

Filing Flows › Companies › Nuo Therapeutics › Cash flow

Nuo Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$490K in Q2 2026 · −$2.4M over twelve months

Operating cash flow−$236K
Capital spending−$253K
Free cash flow−$490K
Cash conversion cycle20 days

Analysis

In Q2 2026, Nuo Therapeutics generated −$236K of operating cash flow and spent $253K on capital projects, leaving free cash flow of −$490K. That is $750K less than in Q2 2025 ($261K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$2.1M; the largest uses were operating cash flow ($2.1M), capital spending ($297K); besides operations, cash came from net borrowing (+) / repaid (−) ($1.7M), other financing ($905K); the cash balance rose by $133K.

Operating cash flow was −$236K against net income of −$278K. The largest differences: receivables −$294K, payables +$178K, deferred revenue −$78K.

Its cash conversion cycle was 20 days (receivables 53 + inventory 39 − payables 72).

Free cash flow

Nuo Therapeutics: free cash flow by quarterNuo Therapeutics: free cash flow by quarter−$638KQ3 2024−$491KQ4 2024−$228KQ1 2025$261KQ2 2025−$707KQ3 2025−$466KQ4 2025−$785KQ1 2026−$490KQ2 2026
Operating cash flow less capital spending.
Nuo Therapeutics: operating cash flow against capital spendingNuo Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$487K$151KQ3 2024−$491K$0Q4 2024$2K$230KQ1 2025$262K$2KQ2 2025−$707K$0Q3 2025−$423K$43KQ4 2025−$784K$1KQ1 2026−$236K$253KQ2 2026
Latest (Q2 2026): Operating cash flow −$236K, Capital spending $253K.

Capital allocation, year by year

Nuo Therapeutics: where the cash came from (up) and went (down), by fiscal yearNuo Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$120KFY2021FY2022: Operating cash flow −$3.7MFY2022: Capital spending −$60KFY2022FY2023: Operating cash flow −$3.2MFY2023: Shares issued $2.0MFY2023: Capital spending −$7K$2.0MFY2023FY2024: Operating cash flow −$2.2MFY2024: Shares issued $1.6MFY2024: Capital spending −$155K$1.6MFY2024FY2025: Operating cash flow −$865KFY2025: Net borrowing $500KFY2025: Shares issued $905KFY2025: Capital spending −$275K$1.4MFY2025
Over these 5 years operating cash flow totalled −$10.1M; the largest uses were operating cash flow ($10.1M) and capital spending ($497K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$449K
Debtnone
Net cash$449K
Cash runway2 months

Nuo Therapeutics is burning cash: its operations consume cash, a free cash flow of −$2.4M a year at the current rate against $449K of cash and investments: a runway of about 2 months before any new financing.

Where the cash came from and went

Nuo Therapeutics: sources (+) and uses (−) of cash, Q2 2026Nuo Therapeutics: sources (+) and uses (−) of cash, Q2 2026Net borrowing (+) / repaid (−)$675KCapital spending−$253KOperating cash flow−$236KCash drawn (+) / kept (−)−$185K
Nuo Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Nuo Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$2.1MNet borrowing (+) / repaid (−)$1.7MOther financing$905KCapital spending−$297KCash drawn (+) / kept (−)−$133K

From profit to cash

Nuo Therapeutics: net income to operating cash flow, Q2 2026Nuo Therapeutics: net income to operating cash flow, Q2 2026Net income−$278KDepreciation & amortization$26KStock-based pay$41KReceivables−$294KInventory−$21KPayables$178KAccrued liabilities$26KDeferred revenue−$78KOperating cash flow−$236K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202653397220
Q1 202650468214
Q4 20255147104-7
Q3 2025434291-6
Q2 20253976278-164
Q1 20254993328-186
Q4 202467169322-85
Q3 202479176358-104

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$236K−$253K$675K—−$185K−$490K
Q1 2026−$784K−$1K$500K$114K$285K−$785K
Q4 2025−$423K−$43K——−$34K−$466K
Q3 2025−$707K——$791K−$198K−$707K
Q2 2025$262K−$2K——−$261K$261K
Q1 2025$2K−$230K——$228K−$228K
Q4 2024−$491K——$90K$400K−$491K
Q3 2024−$487K−$151K—$849K−$211K−$638K

Nuo Therapeutics: income statement and cash flow

Nuo Therapeutics, Q2 2026: revenue $1.8M (+153% year over year), operating margin -9.4%. The chart follows the revenue to costs, profit and cash.

Nuo Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.